Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tamar Tadmor

Showing results (81-90 of 149) with videos related to

Pageof 15
Sort By:
Annals of Hematology|May 25, 2012
Cell surface expression of CD25 antigen (surface IL-2 receptor α-chain) is not a prognostic marker in chronic lymphocytic leukemia: results of a retrospective study of 281 patientsLev Shvidel, Andrei Braester, Osnat Bairey, et al.
Cancer|August 12, 2022
Impact of acupuncture and integrative therapies on chemotherapy-induced peripheral neuropathy: A multicentered, randomized controlled trialEran Ben-Arye, David Hausner, Noah Samuels, et al.
Leukemia Research|February 12, 2013
Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomasAlessia Bari, Tamar Tadmor, Stefano Sacchi, et al.
Frontiers in Immunology|March 1, 2021
The Role of Alpha 2 Macroglobulin in IgG-Aggregation and Chronic Activation of the Complement System in Patients With Chronic Lymphocytic LeukemiaNaseba Naseraldeen, Regina Michelis, Masad Barhoum, et al.
International Journal of Molecular Sciences|January 11, 2024
The Involvement of LAG-3<sup>positive</sup> Plasma Cells in the Development of Multiple MyelomaNatalia Kreiniz, Nasren Eiza, Tamar Tadmor, et al.
Anticancer Research|February 11, 2014
Hodgkin's variant of Richter transformation in chronic lymphocytic leukemia; a retrospective study from the Israeli CLL study groupTamar Tadmor, Lev Shvidel, Neta Goldschmidt, et al.
Scientific Reports|November 5, 2025
Virtual reality and hypnosis for symptom alleviation before bone marrow procedureIlana Levy Yurkovski, Dina Libes, Maya Meiseles, et al.
Hematological Oncology|February 14, 2019
Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experienceYair Herishanu, Tamar Tadmor, Andrei Braester, et al.
Blood|December 3, 2021
Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccinationYair Herishanu, Galia Rahav, Shai Levi, et al.
American Journal of Hematology|August 12, 2014
Richter's transformation to diffuse large B-cell lymphoma: a retrospective study reporting clinical data, outcome, and the benefit of adding rituximab to chemotherapy, from the Israeli CLL Study GroupTamar Tadmor, Lev Shvidel, Osnat Bairey, et al.
Pageof 15

Showing results (81-90 of 149) with videos related to

Sort By:
Pageof 15
Annals of Hematology|May 25, 2012
Cell surface expression of CD25 antigen (surface IL-2 receptor α-chain) is not a prognostic marker in chronic lymphocytic leukemia: results of a retrospective study of 281 patientsLev Shvidel, Andrei Braester, Osnat Bairey, et al.
Cancer|August 12, 2022
Impact of acupuncture and integrative therapies on chemotherapy-induced peripheral neuropathy: A multicentered, randomized controlled trialEran Ben-Arye, David Hausner, Noah Samuels, et al.
Leukemia Research|February 12, 2013
Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomasAlessia Bari, Tamar Tadmor, Stefano Sacchi, et al.
Frontiers in Immunology|March 1, 2021
The Role of Alpha 2 Macroglobulin in IgG-Aggregation and Chronic Activation of the Complement System in Patients With Chronic Lymphocytic LeukemiaNaseba Naseraldeen, Regina Michelis, Masad Barhoum, et al.
International Journal of Molecular Sciences|January 11, 2024
The Involvement of LAG-3<sup>positive</sup> Plasma Cells in the Development of Multiple MyelomaNatalia Kreiniz, Nasren Eiza, Tamar Tadmor, et al.
Anticancer Research|February 11, 2014
Hodgkin's variant of Richter transformation in chronic lymphocytic leukemia; a retrospective study from the Israeli CLL study groupTamar Tadmor, Lev Shvidel, Neta Goldschmidt, et al.
Scientific Reports|November 5, 2025
Virtual reality and hypnosis for symptom alleviation before bone marrow procedureIlana Levy Yurkovski, Dina Libes, Maya Meiseles, et al.
Hematological Oncology|February 14, 2019
Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experienceYair Herishanu, Tamar Tadmor, Andrei Braester, et al.
Blood|December 3, 2021
Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccinationYair Herishanu, Galia Rahav, Shai Levi, et al.
American Journal of Hematology|August 12, 2014
Richter's transformation to diffuse large B-cell lymphoma: a retrospective study reporting clinical data, outcome, and the benefit of adding rituximab to chemotherapy, from the Israeli CLL Study GroupTamar Tadmor, Lev Shvidel, Osnat Bairey, et al.
Pageof 15